Total Payments
$3,635
2024 Payments
$360.83
Companies
19
Transactions
61
Medicare Patients
2,579
Medicare Billing
$353,305
Payment Breakdown by Category
Food & Beverage$3,572 (98.3%)
Education$62.88 (1.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,572 | 54 | 98.3% |
| Education | $62.88 | 7 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $894.43 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $495.80 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $290.48 | 4 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $275.68 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $222.32 | 2 | $0 (2017) |
| Genentech USA, Inc. | $190.59 | 2 | $0 (2017) |
| Eisai Inc. | $173.73 | 5 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $137.47 | 1 | $0 (2017) |
| PFIZER INC. | $137.10 | 5 | $0 (2018) |
| GENZYME CORPORATION | $133.80 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $360.83 | 9 | Merck Sharp & Dohme LLC ($148.98) |
| 2023 | $280.15 | 4 | GENZYME CORPORATION ($133.80) |
| 2022 | $424.08 | 8 | Incyte Corporation ($228.11) |
| 2021 | $344.53 | 6 | Incyte Corporation ($210.86) |
| 2020 | $293.05 | 5 | Incyte Corporation ($124.61) |
| 2019 | $148.57 | 3 | Janssen Biotech, Inc. ($120.40) |
| 2018 | $623.39 | 13 | PFIZER INC. ($137.10) |
| 2017 | $1,161 | 13 | E.R. Squibb & Sons, L.L.C. ($290.48) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $5.54 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $5.09 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Oncology | ||||||
| 05/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $126.33 | General |
| Category: Hematology/Oncology | ||||||
| 02/01/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $113.97 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: ONCOLOGY | ||||||
| 03/09/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $119.37 | General |
| Category: Oncology | ||||||
| 03/01/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $13.81 | General |
| 02/09/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $133.80 | General |
| Category: Oncology | ||||||
| 11/30/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $116.06 | General |
| Category: Oncology | ||||||
| 08/30/2022 | Incyte Corporation | PEMAZYRE (Drug) | Food and Beverage | Cash or cash equivalent | $112.33 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 08/24/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $14.58 | General |
| Category: Oncology | ||||||
| 08/18/2022 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $115.78 | General |
| Category: Hematology/Oncology | ||||||
| 08/02/2022 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Education | In-kind items and services | $26.69 | General |
| Category: Oncology | ||||||
| 06/29/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2022 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $10.28 | General |
| Category: Oncology | ||||||
| 03/30/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2021 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $11.53 | General |
| Category: Oncology | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2021 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $16.56 | General |
| Category: Hematology/Oncology | ||||||
| 04/27/2021 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $103.25 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 639 | 1,163 | $214,823 | $84,541 |
| 2022 | 11 | 689 | 1,324 | $224,088 | $96,008 |
| 2021 | 10 | 622 | 1,264 | $207,535 | $91,626 |
| 2020 | 11 | 629 | 1,187 | $201,538 | $81,130 |
Total Patients
2,579
Total Services
4,938
Medicare Billing
$353,305
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 201 | 508 | $90,934 | $36,218 | 39.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 85 | 173 | $34,818 | $18,804 | 54.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 172 | 278 | $39,613 | $12,282 | 31.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 27 | $11,771 | $3,706 | 31.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 43 | $7,490 | $2,692 | 35.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 26 | $6,978 | $2,449 | 35.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $7,763 | $2,369 | 30.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $4,830 | $2,144 | 44.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $5,036 | $1,855 | 36.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $4,314 | $1,438 | 33.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 19 | 26 | $1,276 | $584.85 | 45.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 201 | 549 | $85,993 | $39,482 | 45.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 86 | 176 | $29,980 | $19,430 | 64.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 185 | 315 | $43,175 | $14,576 | 33.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 27 | 29 | $13,775 | $4,517 | 32.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 51 | $12,495 | $4,107 | 32.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 36 | $12,600 | $3,828 | 30.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 33 | 60 | $10,200 | $3,368 | 33.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $5,214 | $2,329 | 44.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $5,486 | $2,037 | 37.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 27 | 50 | $1,700 | $1,251 | 73.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 19 | 19 | $3,470 | $1,084 | 31.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 187 | 530 | $83,844 | $39,591 | 47.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 77 | 167 | $29,456 | $18,480 | 62.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 171 | 309 | $40,588 | $14,859 | 36.6% |
About Dr. David Ernst, D.O
Dr. David Ernst, D.O is a Hematology & Oncology healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639115827.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ernst, D.O has received a total of $3,635 in payments from pharmaceutical and medical device companies, with $360.83 received in 2024. These payments were reported across 61 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($3,572).
As a Medicare-enrolled provider, Ernst has provided services to 2,579 Medicare beneficiaries, totaling 4,938 services with total Medicare billing of $353,305. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Kansas City, MO
- Active Since 06/22/2006
- Last Updated 03/08/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1639115827
Products in Payments
- JAKAFI (Drug) $782.10
- KEYTRUDA (Biological) $480.16
- ELIQUIS (Drug) $324.47
- Lenvima (Drug) $173.73
- LYNPARZA (Drug) $142.50
- Imbruvica (Drug) $137.47
- SARCLISA (Biological) $133.80
- Nerlynx (Drug) $132.03
- IMBRUVICA (Drug) $120.40
- TAGRISSO (Drug) $119.37
- TECENTRIQ (Biological) $118.78
- Enhertu (Drug) $117.14
- RYDAPT (Drug) $115.51
- PEMAZYRE (Drug) $112.33
- KISQALI (Drug) $106.81
- ADCETRIS (Biological) $103.25
- Oncology (Device) $98.87
- OPDIVO (Biological) $92.71
- Rituxan (Biological) $71.81
- OJJAARA (Drug) $40.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Kansas City
Dr. Suman Kambhampati, Md, MD
Hematology & Oncology — Payments: $281,918
Hematology & Oncology $281,918
Dr. Shahzad Raza, Md, MD
Hematology & Oncology — Payments: $184,113
Hematology & Oncology $184,113
Joseph Mcguirk, D.o, D.O
Hematology & Oncology — Payments: $129,700
Hematology & Oncology $129,700
Dr. Stephanie Graff, M.d, M.D
Hematology & Oncology — Payments: $120,151
Hematology & Oncology $120,151
Jaswinder Singh, Md, MD
Hematology & Oncology — Payments: $86,702
Hematology & Oncology $86,702
Dr. Tara Lin, Md, MD
Hematology & Oncology — Payments: $24,114
Hematology & Oncology $24,114